Casdin Capital
Crossover fundNew York · Seed–Series C · 39 people tracked
Also known as CASDIN CAPITAL, LLC
Investment thesis
Casdin Capital invests across the life sciences sector, spanning healthcare, biotechnology, synthetic biology, and technology. The firm believes great medicines make great investments and targets companies leveraging the growing ability to read and manipulate molecular information. Its approach centers on partnering with companies and building positions to create value over time, emphasizing patience, persistence, and strong relationships. The firm's guiding formula is to aim at large markets, back great ideas and teams, stay focused, and avoid hubris. With decades of experience, Casdin positions itself as one of the few expert investors in the field.
Source: firm website, verified Aug 25, 2026.
Team · 39 people
from the firm's website
What they invest in
from 33 of 35 portfolio companiesBiotech ×25AI & Machine Learning ×13Deep Tech ×11Healthtech ×11Medical Devices ×7Data & Infrastructure ×3Digital Health ×3Enterprise Software ×3
HQs:United States×26United Kingdom×1Japan×1Kenya×1Netherlands×1
Investments · 35 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22024 · 12023 · 12021 · 72020 · 32018 · 22017 · 120 dated
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Board seatEli Casdin· per SEC Form D · $125M raise · filed Mar 2021
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesBiotechnology Value Fund+2 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer.
BiotechHealthtechMedical DevicesPhiladelphia, US
Board seatEli Casdin· per SEC Form D · $160M raise · filed Mar 2021
Co-investorsVersant Ventures
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.
BiotechDeep TechHealthtechLeiden, NL
Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)Jintanat Ananworanich(Chief Medical Officer)Clarissa Koch(Chief Scientific Officer)
Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesEuropean Innovation Council FundEuropean Investment Bank+5 more
C2i Genomics develops TrueMRD, a cancer monitoring platform that combines whole-genome sequencing with AI algorithms to build personalized tumor signatures for detecting minimal residual disease (MRD).
AI & Machine LearningBiotechHealthtechNew York, US
Asaf Zviran(Founder)inEzra Sofer(Executive Officer, Director)
BoardAlex Parker(Director)Shaun Rodriguez(Director)in
Board seatEli Casdin· per SEC Form D
Co-investorsiGlobe PartnersLionBirdNFXSection 32
BiotechCambridge, US
Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Chris Bowden(Director)Jake Simson(Director)Rosana Kapeller(Director)
BoardAbbie Celniker(Director)in
Board seatEli Casdin· per SEC Form D · $82.6M raise · filed Oct 2021
Co-investorsThird Rock Ventures
Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.
BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US
Christophe Schilling(Co-founder (former CEO))Bernhard Palsson(Co-founder)Thomas McDonald(Executive Officer)Carlos A. Cabrera(Executive Chairman)John G. Gugel(Chief Executive Officer)Tom McDonald(SVP, Finance & Chief Financial Officer)
Board seatEli Casdin· per SEC Form D · $119.1M raise · filed Aug 2021
Co-investorsVantagePoint Capital PartnersNovo Holdings
HealthtechNew York, US
David Klimstra(Executive Officer)Thomas Fuchs(Director)William Andrew Moye(Executive Officer, Director)Peter Hamilton(Executive Officer)Antoine Munfa(Director)Jim Beyer(Director)
Board seatEli Casdin· per SEC Form D · $39M raise · filed Mar 2023
Co-investorsCatalio Capital Management, LP
SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.
BiotechDeep TechHealthtechBoulder, US
Larry Gold(Director)Larry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)
BoardCharles Lillis(Director)Youichi Yabuuchi(Director)
Board seatEli Casdin· per SEC Form D · $250M raise · filed Jan 2021
Co-investorsForesite CapitalKhosla Ventures
BiotechSan Francisco, US
Amy Duross(Executive Officer)Jason Bowman(Executive Officer)
BoardNigel Darby(Director)Rowan Chapman(Director)
Board seatEli Casdin· per SEC Form D · $75M raise · filed Nov 2020
Co-investorsCanaan PartnersThreshold Ventures
23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery.
BiotechDigital HealthDirect to ConsumerHealthtechLongevityMountain View, US
Anne Wojcicki(Co-founder & CEO)inLinda Avey(Co-founder)Paul Cheung(Co-founder)Andrew Page(Executive Officer, Director)Kathy Hibbs(Executive Officer)
BoardEsther Dyson(Director)
Co-investorsAllied Venture PartnersCivilization Ventures Management, LlcEQUIAMG SquaredHouston Angel NetworkInvestX+12 more
Asimov collects real-world human activity data at scale from diverse environments to create annotated datasets for training robotics AI models.
Advanced ManufacturingAI & Machine LearningData & InfrastructureRoboticsSan Francisco, US
Lyem Ningthou(Founder)in
Co-investorsY CombinatorAME Cloud VenturesAndreessen Horowitz
Asimov develops a computer-aided design platform for genetic engineering, enabling designers to program living cells by applying abstraction, standardization, and modeling to biology.
AI & Machine LearningBiotechDeveloper ToolsBoston, US
Chris Voigt(Co-founder)inDoug Densmore(Co-founder)Alec Nielsen(Co-founder & CEO)inRaja Srinivas(Co-founder)in
Co-investorsAndreessen HorowitzDCVC (Data Collective)K5 GlobalKoch Disruptive TechnologiesPillar VCAME Cloud Ventures
Asimov builds a computer-aided design platform for genetic engineering and synthetic biology, enabling genetic designers to program living cells through automated circuit design and computational modeling.
AI & Machine LearningBiotechDeep TechBoston, US
Chris Voigt(Co-founder)Doug Densmore(Co-founder)Alec Nielsen(Co-founder & CEO)Raja Srinivas(Co-founder)in
Co-investorsAndreessen HorowitzWingAME Cloud Ventures
Boston, US
Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jarrett Revels(Executive Officer)Jacob A. Donoghue(Executive Officer, Director, Promoter)
BoardCaitlin Donovan(Director)Pavel Raifeld(Director)Naveen Rao(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystGV (Google Ventures)Iaso VenturesKicker VenturesIndicator Ventures+1 more
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesFidelity InvestmentsInvusRock Springs Capital
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)Leandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsBain Capital Life SciencesVenrock Healthcare Capital Partners
Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases.
AI & Machine LearningBiotechWatertown, US
Eric Kelsic(CEO & Cofounder)inSam Sinai(Vice President, Head of ML & Cofounder)inAdrian Veres(Chief Scientific Officer & Cofounder)George Church(Scientific Cofounder)Tomas Bjorklund(Scientific Co-founder)Alan Crane(Executive Chairman & Cofounder, Polaris Entrepreneur Partner)
Co-investorsAndreessen HorowitzCRV (Charles River Ventures)GENERAL INCEPTIONGV (Google Ventures)Lux CapitalObvious Ventures+2 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalNovartis Venture Fund
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Martin Reese(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)
Co-investorsArtis VenturesForesite CapitalMighty Capital
Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.
Enterprise SoftwareGovTechSaaSNairobi, KE
Co-investors4Di CapitalInovia CapitalAgent CapitalBase10 PartnersInvusNextech Invest+3 more
Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.
Crypto & Web3Data & Infrastructure
Co-investorsDigital Currency GroupAgent CapitalBase10 PartnersInovia CapitalInvusNextech Invest+3 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalBase10 PartnersInovia Capital+5 more
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)Maureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Co-investorsB3 HoldingNextech InvestSoftBank Vision FundThe Column Group8VCTwo Sigma Ventures
insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.
AI & Machine LearningBiotechSouth San Francisco, US
Daphne Koller(CEO & Founder)inDuane Valz(General Counsel)Mary Rozenman(Chief Financial Officer)
BoardRobert Nelsen(Director)Vijay Pande(Director)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+5 more
Komodo integrates healthcare data across providers, health systems, care settings, and payers to deliver insights on disease incidence, treatment patterns, and health outcomes.
AI & Machine LearningData & InfrastructureHealthtechSan Francisco, US
Dr. Arif Nathoo(Co-Founder/Co-CEO)Web Sun(Co-Founder/Co-CEO)inArif Nathoo(Founder)in
Co-investorsAndreessen HorowitzCoatue ManagementFelicis VenturesICONIQMcKesson VenturesOak HC/FT+4 more
Lyra provides mental health care services through a network of evidence-based providers, combining clinical expertise with technology to deliver accessible, quality care for employers and health plans.
Digital HealthEnterprise SoftwareHealthtechHR TechMental HealthBurlingame, US
David Ebersman(Co-Founder & Chairman (CEO 2015–2025))inBob Kocher(Co-Founder and Board Member)inDena Bravata(Co-Founder & former Chief Medical Officer)Alethea Varra(Vice President of Clinical Care)Jennifer Schulz(Chief Executive Officer)Elaine Yang(Executive Officer)
Co-investorsAdditionBreyer CapitalCoatue ManagementDragoneer Investment GroupDurable Capital PartnersFidelity Investments+11 more
New York, US
Koda Mike Wang(Executive Officer, Director)
BoardTimothy Luke Sherwin(Director)
Co-investorsGreylock PartnersTenaya CapitalVenrock
Meiogenix develops a proprietary recombination technology that targets meiotic recombination to accelerate genetic gain and variety development in crops.
AgTechBiotechDeep Tech
Ricardo Garcia de Albain
Co-investorsGenoa VenturesKurma PartnersSofinnova Partners
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.
BiotechDeep TechNew MaterialsSan Diego, US
J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)
BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)John Nicols(Director)Todd Peterson(Director)
Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundAlexandriaArgonautic VenturesKeshif Ventures+1 more
Multiply Labs builds robotic systems that automate biologics manufacturing for pharmaceutical companies.
Advanced ManufacturingBiotechDeep TechRoboticsSan Francisco, US
Fred Parietti(Founder/CEO)inAlice Melocchi(Founder)in
BoardShaun Rodriguez(Director)inMichael Doherty(Director)
Co-investorsFifty YearsGarage CapitalP101 VenturesStrange VenturesY CombinatorGraph Ventures+1 more
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Co-founder)inRamsey Homsany(Founder)in
Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPFifty Years+5 more
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture Partners
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Co-investorsAisling CapitalARCH Venture PartnersOrbiMedFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande
Maran Vedamanikam(CEO and Manager)
Co-investorsSamsung NextAndreessen HorowitzWndrCoBiotechnology Value FundFonds de solidarité FTQGV (Google Ventures)+4 more
BiotechSan Francisco, US
Kaz Ohno(Executive Officer)James Lim(Executive Officer)Brian S. Feth(Executive Officer, Director)
BoardSaeid Akhtari(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioAbsciNASDAQ: ABSICentury Therapeutics, Inc.NASDAQ: IPSC
Portfolio news
latest coverage across their companies
SomaLogic · aol.com · Aug 4, 2026
Flare · coindesk.com · Jul 30, 2026
Flare · allsci.com · Jul 1, 2026
Flare · allsci.com · Jul 1, 2026
Leyden Labs · firstwordpharma.com · Jun 29, 2026
Absci · investing.com · Jun 25, 2026
Treeline Biosciences · watertown.bio · Jun 23, 2026
Fabric Genomics · hartfordbusiness.com · Jun 22, 2026
Frequently asked questions
- What stage does Casdin Capital invest at?
- Casdin Capital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Casdin Capital focus on?
- Casdin Capital focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Casdin Capital located?
- Casdin Capital is headquartered in New York, US.
- Does Casdin Capital lead rounds?
- Casdin Capital typically participates in rounds rather than leading them.
- Who does Casdin Capital co-invest with?
- Casdin Capital most often shares deals with Breyer Capital, Greylock Partners, IVP (Institutional Venture Partners), among 12 tracked co-investors.
Media · Podcasts & interviews
featuring the teamEli Casdin – Casdin Capital (Manager Meetings, EP.02)
Capital Allocators with Ted Seides · Eli Casdin
The full interview with Casdin Capital's Eli Casdin
Eli Casdin · cnbc.com
Co-investors · 10
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Bluebird Ventures backs founders and entrepreneurs building start-ups that advance medical science.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
S32 is a high-conviction venture firm that concentrates on a small set of core relationships, committing deeply and supporting founders over the long term.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Firms observed investing alongside Casdin Capital, from public investor directories. Shared companies are the overlap with Casdin Capital's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.